Sez who.

A case series of 13 patients receiving brentuximab vedotin, an anti-CD30 monoclonal antibody conjugated to a tubulin toxin, for Sézary syndrome (a condition previously excluded on trials) reports 5 (38%) achieved a “global” response in skin, nodes and blood. Now, pair this with radiation and we may see some breakthroughs in an otherwise bleak disease. | Lewis, JAMA Dermatol 2020

Comments

Popular Posts